165 related articles for article (PubMed ID: 38127899)
1. Molecular and clinical characterization of ICOS expression in breast cancer through large-scale transcriptome data.
Wang P; Zhang Q; Zhang H; Shao J; Zhang H; Wang Z
PLoS One; 2023; 18(12):e0293469. PubMed ID: 38127899
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of the role of ICOS ( CD278 ) in pan-cancer prognosis and immunotherapy.
Zhao X; Wang Y; Jiang X; Mo B; Wang C; Tang M; Rong Y; Zhang G; Hu M; Cai H
BMC Cancer; 2023 Feb; 23(1):194. PubMed ID: 36855091
[TBL] [Abstract][Full Text] [Related]
3. The landscape of
de Vos L; Grünwald I; Bawden EG; Dietrich J; Scheckenbach K; Wiek C; Zarbl R; Bootz F; Landsberg J; Dietrich D
Epigenetics; 2020 Nov; 15(11):1195-1212. PubMed ID: 32281488
[TBL] [Abstract][Full Text] [Related]
4. Role of Inducible Co-Stimulator (ICOS) in cancer immunotherapy.
Amatore F; Gorvel L; Olive D
Expert Opin Biol Ther; 2020 Feb; 20(2):141-150. PubMed ID: 31738626
[No Abstract] [Full Text] [Related]
5. The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy.
Solinas C; Gu-Trantien C; Willard-Gallo K
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 32516116
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
7. Molecular and Clinical Characterization of PD-1 in Breast Cancer Using Large-Scale Transcriptome Data.
Liu Q; Cheng R; Kong X; Wang Z; Fang Y; Wang J
Front Immunol; 2020; 11():558757. PubMed ID: 33329517
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome profile and clinical characterization of ICOS expression in gliomas.
Wang J; Shi F; Shan A
Front Oncol; 2022; 12():946967. PubMed ID: 36276141
[TBL] [Abstract][Full Text] [Related]
9. Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage I-III lung adenocarcinoma patients.
Zhan XK; Liu XK; Zhang S; Chen H
Animal Model Exp Med; 2023 Oct; 6(5):464-473. PubMed ID: 37850501
[TBL] [Abstract][Full Text] [Related]
10. ICOS-L as a Potential Therapeutic Target for Cancer Immunotherapy.
Marinelli O; Nabissi M; Morelli MB; Torquati L; Amantini C; Santoni G
Curr Protein Pept Sci; 2018; 19(11):1107-1113. PubMed ID: 29879883
[TBL] [Abstract][Full Text] [Related]
11. ICOS Is an Indicator of T-cell-Mediated Response to Cancer Immunotherapy.
Xiao Z; Mayer AT; Nobashi TW; Gambhir SS
Cancer Res; 2020 Jul; 80(14):3023-3032. PubMed ID: 32156777
[TBL] [Abstract][Full Text] [Related]
12. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.
Amatore F; Gorvel L; Olive D
Expert Opin Ther Targets; 2018 Apr; 22(4):343-351. PubMed ID: 29468927
[TBL] [Abstract][Full Text] [Related]
13. Exosome miR-27a-3p secreted from adipocytes targets ICOS to promote antitumor immunity in lung adenocarcinoma.
Fan X; Wang J; Qin T; Zhang Y; Liu W; Jiang K; Huang D
Thorac Cancer; 2020 Jun; 11(6):1453-1464. PubMed ID: 32212417
[TBL] [Abstract][Full Text] [Related]
14. ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.
Hanson A; Elpek K; Duong E; Shallberg L; Fan M; Johnson C; Wallace M; Mabry GR; Sazinsky S; Pepper L; Shu CJ; Sathyanarayanan S; Zuerndorfer S; Simpson T; Gostissa M; Briskin M; Law D; Michaelson J; Harvey CJ
PLoS One; 2020; 15(9):e0239595. PubMed ID: 32970735
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional profile and immune infiltration in colorectal cancer reveal the significance of inducible T-cell costimulator as a crucial immune checkpoint molecule.
Chu J; Wu Y; Qu Z; Zhuang J; Liu J; Han S; Wu W; Han S
Cancer Med; 2024 Mar; 13(6):e7097. PubMed ID: 38506253
[TBL] [Abstract][Full Text] [Related]
17. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples.
Liu Q; Qi Y; Zhai J; Kong X; Wang X; Wang Z; Fang Y; Wang J
Front Immunol; 2021; 12():599207. PubMed ID: 34267742
[TBL] [Abstract][Full Text] [Related]
18. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells.
Faget J; Bendriss-Vermare N; Gobert M; Durand I; Olive D; Biota C; Bachelot T; Treilleux I; Goddard-Leon S; Lavergne E; Chabaud S; Blay JY; Caux C; Ménétrier-Caux C
Cancer Res; 2012 Dec; 72(23):6130-41. PubMed ID: 23026134
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
20. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
